PAA

2.63%

19.5¢ pharmaust limited

Alzheimer's and Monepantel, page-3

First 3 Last

Share
Profile

Follow
Jakjazz

2,951 Posts.

1085

04/01/24

15:09

Post #: 71726572
Share

Originally posted by kpax: ↑

Hi all, ( apologies a technical post)

Alzheimer's so research follows affects 6.2 million people in the USA. By 2050 that number is estimated to be 82 million.

Monepantel is a positive allosteric modulator of DEG3/DES2 type nicotinic acetylcholine receptors ( nACHRs).

Do the nAChRs mediate Ab induced tau pathology which are implicated in Alzheimer's.Dated research shows yes .

"A7 nicotinic acetylcholine receptor mediate B-Amyloid peptide induced tau protein phosphorylation. Wang 2003.

Loss of acetylcholine in the hippocampus and neocortex is closely associated with Alzheimer's disease.By restoring nicotinic acetylcholine receptors it would select targets for attenuating neurodegenerative
disease. Rationale is thus:

nAChRs promote the release of catecholamines stimulated by loss of acetylcholine AcH. These participate in the memory process of the interaction between the cerebral cortex and the hippocampus and consolidate memory.nAChRs regulate choline energy nerve pressure and effects nerve circuit function it also inhibits neuron excitability and negative feedback.

In 2024 we assume amyloid B plaque is the primary agent for tau hyperphosphorylation. Thus the main contributor to Alzheimer's pathogenesis.This is suggested by this study.

" Nicotinic acetylcholine receptors: Key targets for attenuating neurodegenerative disease. Bye et al 2023. They state :

Nicotinic acetylcholine receptors (nAChRs) are master regulators of immune functions via the cholinergic anti-inflammatory pathway and are expressed in microglia, the brain’s resident immune cells. There is an extensive dialogue between the neurons and the glial cells around them from which microglia are tasked with monitoring, nurturing, and defending their microenvironment. Dysregulation of any of these processes can have devastating and long-lasting consequences involving microglia-mediated neuroinflammation associated with neurodegenerative diseases such as Alzheimer’s disease.

A very brief overview of Monepantel and Alzheimer's.

Kpax

Expand

kpax, I am a mental midget when it comes to understanding your medical posts but I do get the underlying messages and greatly appreciate you sharing your knowledge and the medical potential of MPL. I have huge faith in the science and therefore believe we have great milestones before us all primarily the MND patients.

Personally I am hopeful that MPL is also advanced in the treatment of human cancer.

Thank you and GLTAH

PAA Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 16 more messages in this thread...

First 3 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change 0.005(2.63%)		Mkt cap ! $94.89M

Open	High	Low	Value	Volume
19.0¢	19.5¢	19.0¢	$58.40K	305.6K

Buyers (Bids)

No.	Vol.	Price($)
2	115000	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	86074	3

View Market Depth

No.	Vol.	Price($)
1	100000	0.190
8	156232	0.185
10	635662	0.180
10	482365	0.175
8	151233	0.170

Price($)	Vol.	No.
0.195	86074	3
0.200	256824	3
0.205	113150	5
0.210	333355	8
0.215	266995	7

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAA (ASX) Chart

Alzheimer's and Monepantel, page-3

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Alzheimer's and Monepantel, page-3

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News